Embecta
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 2.2K
- Market Cap
- -
- Introduction
Embecta Corp. engages in the provision of medical devices used in the treatment of diabetes. Its products include pen needles, syringes, and safety devices complemented by a digital application. The company was founded in 1924 and is headquartered in Parsippany, NJ.
Clinical Trials
1
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Embecta AID System in Adults With Type 2 Diabetes
- Conditions
- Type 2 DiabetesType 2 Diabetes Mellitus (T2DM)Type 2 DMT2DM With Inadequate Glycemic ControlT2DM (Type 2 Diabetes Mellitus)T2DT2DM
- First Posted Date
- 2024-11-18
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Embecta Corp.
- Target Recruit Count
- 360
- Registration Number
- NCT06692153
- Locations
- 🇺🇸
Stanford, Palo Alto, California, United States
🇺🇸Diablo Research, Walnut Creek, California, United States
🇺🇸Indiana Universtiy School of Medicine, Indianapolis, Indiana, United States
News
Regulatory Updates in Cardiometabolic Health: Hypertension, Lipids, and Diabetes Therapies
The FDA approved an expanded indication for subcutaneous furosemide injection for heart failure patients, offering a convenient self-administration option.
September 2024: FDA Actions Span Diabetes, Neurology, and Rare Diseases
• The FDA approved Embecta's tubeless patch pump for insulin delivery in adults with type 1 and type 2 diabetes, offering a 300-unit reservoir based on patient feedback. • Sparsentan (Filspari) received full FDA approval to slow kidney function decline in adults with primary IgA nephropathy (IgAN), based on positive Phase 3 PROTECT study data. • Approvals for arimoclomol (Miplyffa) and levacetylleucine (Aqneursa) mark the first specific treatments for neurological symptoms of Niemann-Pick disease type C (NPC). • Dupilumab (Dupixent) gained approval for COPD, chronic rhinosinusitis with nasal polyps, and was submitted for label expansion for adult growth hormone deficiency.
Embecta's Tubeless Insulin Patch Pump Receives FDA Clearance for Diabetes Management
Embecta Corp. secures FDA 510(k) clearance for its tubeless insulin patch pump designed for adults with type 1 and type 2 diabetes.
FDA Approves Digital Therapeutic for GAD, Updated Novavax COVID-19 Vaccine, and New Insulin Patch Pump
• The FDA cleared DaylightRX, the first digital therapeutic for generalized anxiety disorder (GAD), to be used as an adjunct to usual care for patients aged 22 years and older. • Novavax received emergency use authorization (EUA) from the FDA for its updated COVID-19 vaccine, NVX-CoV2705, for individuals aged 12 years and older. • Embecta gained FDA 510(k) clearance for its disposable insulin delivery system, designed for adults with type 1 and type 2 diabetes, featuring a 300-unit reservoir.